Hematologic cancer drug prices not cost-effective, may compromise patient adherence
the ONA take:
Researchers at The University of Texas MD Anderson Cancer Center conducted a study on current hematologic cancer drug prices and its potential impact on cancer care.
They found that the majority of existing drugs for hematologic cancers are priced too high to be considered cost-effective in the United States.
Substantial improvements in survival and quality of life have been achieved in recent years. However, rising drug prices may force many patients to choose between continuing their drug treatment plans or saving money for their families’ future.
Cost-effectiveness is commonly interpreted in terms of the cost needed to gain an additional quality year of life. A widely accepted threshold value is $50,000; costs below this amount are considered cost-effective.
The researchers re-analyzed results of 20 studies on drugs for various hematologic cancers, using current drug prices in US dollars. They found that costs exceed the $50,000 threshold in 63% of the studies.
The increase in drug prices is not due to new and improved versions of the drugs; it is simply due to drug companies charging higher prices for their drugs.
The researchers conclude that following the European practice of regulating the costs of new treatments will make health care more affordable and valuable for both patients and providers in the United States.
Majority of existing drugs for hematologic cancers are priced too high to be considered cost-effective in the United States.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Nasal Biomarker in Smokers Could Predict Lung Cancer
- Arm Lymphoscintigraphy After Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy in Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|